Program Description

In the United States, almost 50,000 new cases of pulmonary fibrosis — a disease that causes progressive scarring of the lung tissue — are diagnosed annually, including among some first responders to Ground Zero in New York. There are no treatment options, but early research has begun in hopes of one day treating this deadly disease, as Bob Baltera, chief executive officer of Amira Pharmaceuticals explains to host Bruce Japsen. Amira Pharmaceuticals is a San Diego-based company focused on the discovery and early development of compounds to treat inflammatory disease.

Series

Clinician's Roundtable

Guest

Hosted by